TY - JOUR
T1 - Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
AU - Alter, Galit
AU - Yu, Jingyou
AU - Liu, Jinyan
AU - Chandrashekar, Abishek
AU - Borducchi, Erica N.
AU - Tostanoski, Lisa H.
AU - McMahan, Katherine
AU - Jacob-Dolan, Catherine
AU - Martinez, David R.
AU - Chang, Aiquan
AU - Anioke, Tochi
AU - Lifton, Michelle
AU - Nkolola, Joseph
AU - Stephenson, Kathryn E.
AU - Atyeo, Caroline
AU - Shin, Sally
AU - Fields, Paul
AU - Kaplan, Ian
AU - Robins, Harlan
AU - Amanat, Fatima
AU - Krammer, Florian
AU - Baric, Ralph S.
AU - Le Gars, Mathieu
AU - Sadoff, Jerald
AU - de Groot, Anne Marit
AU - Heerwegh, Dirk
AU - Struyf, Frank
AU - Douoguih, Macaya
AU - van Hoof, Johan
AU - Schuitemaker, Hanneke
AU - Barouch, Dan H.
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/8/12
Y1 - 2021/8/12
N2 - The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase I–IIa clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1 and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titres that were 5.0-fold and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 after vaccination. Median binding antibody titres were 2.9-fold and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition and natural killer cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1 and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.
AB - The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase I–IIa clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1 and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titres that were 5.0-fold and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 after vaccination. Median binding antibody titres were 2.9-fold and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition and natural killer cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1 and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.
UR - https://www.scopus.com/pages/publications/85107435483
U2 - 10.1038/s41586-021-03681-2
DO - 10.1038/s41586-021-03681-2
M3 - Article
C2 - 34107529
AN - SCOPUS:85107435483
SN - 0028-0836
VL - 596
SP - 268
EP - 272
JO - Nature
JF - Nature
IS - 7871
ER -